Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9833 - 9840 of 12085 results

FTC and DOJ Host Workshop on Health Care Competition
January 30, 2015| Blog| Viewpoint

Even Further Down the Rabbit Hole: New EU Legislation Adds to GMO Quagmire
January 29, 2015| Blog| Viewpoint

DOL Looks to Update/Modernize Sex Discrimination Guidelines for Federal Contractors and Subcontractors
January 29, 2015| Blog| Viewpoint

Massachusetts Expands Its Leave Law to Cover Fathers
January 29, 2015| Blog| Viewpoint

Employers: Don’t Forget About the Possibility of Associational Discrimination Liability
January 29, 2015| Blog| Viewpoint

ML Strategies Posts Weekly Health Care Update on January 26, 2015
January 29, 2015| Blog| Viewpoint

ML Strategies: Keystone XL Pipeline Dominates Congressional Energy Debates to Start New Year
January 28, 2015| Blog| Viewpoint

It's Data Privacy Day 2015
January 28, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
